Tagged Nucleai


Q&A: The startup aiming to improve cancer diagnoses through AI-based analysis of biopsies

Web content editor Ian Bolland caught up with Avi Veidman, CEO of pathology startup Nucleai which aims to make cancer diagnoses more accurate, accessible and efficient through AI-based analysis of biopsies. Give us an idea of the ‘comprehensive suite of solutions that Nucleai offers? Nucleai provides a comprehensive suite of solutions for cancer biopsies relating to gastro, breast and prostate…


Precision AI company collaborates with biotech firm to enhance cancer diagnosis

Precision AI company Nucleai has is partnering with biotech company Protean BioDiagnostics, to commercialise advanced cancer diagnostic technology. Nucleai and Protean BioDiagnostics are launching a co-branded campaign, Protean QA Service Enhancement powered by Nucleai, that will pair Nucleai’s AI services with Protean BioDiagnostic laboratories’ diagnostic tools. This service will be deployed in labs, hospitals, and urology centres across…

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions